<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03147066</url>
  </required_header>
  <id_info>
    <org_study_id>20170110</org_study_id>
    <nct_id>NCT03147066</nct_id>
  </id_info>
  <brief_title>Dezocine for Prevention of Catheter-related Bladder Discomfort</brief_title>
  <official_title>Efficacy of Dezocine for the Prevention of Catheter-related Bladder Discomfort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jian-jun Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongda Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of dezocine in preventing the catheter-related bladder
      discomfort (CRBD) in a postanesthesia care unit (PACU).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty min before the end of the surgery, patients were randomly assigned to one of the two
      group to receive intravenous dezocine 0.1 mg/kg (Group D, n=48) or flurbiprofen axetil 1
      mg/kg (Group F, n=48) . The CRBD was assessed at 0, 1, 2, and 6 h after patient's arrival in
      the post-anaesthesia care unit. Severity of CRBD was graded as none, mild, moderate and
      severe.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">October 30, 2017</completion_date>
  <primary_completion_date type="Actual">October 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Catheter related bladder discomfort symptoms</measure>
    <time_frame>at 1 hour after extubatio</time_frame>
    <description>CRBD will be evaluated with a 4 point scale (1; no discomfort, 2; mild, revealed on questioning only, 3; moderate, stated by the patient without questioning, 4; severe, urinary urgency executed by behavioral responses, such as attempts to remove urinary catheter, restless extremity movements, verbal responses)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Catheter related bladder discomfort symptoms</measure>
    <time_frame>at 0, 1, 2, and 6 hours after extubation</time_frame>
    <description>CRBD will be evaluated with a 4 point scale (1; no discomfort, 2; mild, revealed on questioning only, 3; moderate, stated by the patient without questioning, 4; severe, urinary urgency executed by behavioral responses, such as attempts to remove urinary catheter, restless extremity movements, verbal responses)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of pain at suprapubic area</measure>
    <time_frame>at 0, 1, 2, and 6 hours after extubation</time_frame>
    <description>Pain at suprapubic area will be evaluated using VAS after extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation level</measure>
    <time_frame>at 0, 1, 2, and 6 hours after extubation</time_frame>
    <description>The Ramsay Sedation Scale was measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>at 0, 1, 2, and 6 hours after extubation</time_frame>
    <description>The incidence of nausea, vomiting, hypotension, hypertension, bradycardia,respiratory depression after extubation, and excessive sedation were also recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Catheter Related Bladder Discomfort</condition>
  <arm_group>
    <arm_group_label>Dezocine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 mg/kg of intravenous dezocine 30 min before the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flurbiprofen axetil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 mg/kg of intravenous flurbiprofen axetil 30 min before the end of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dezocine</intervention_name>
    <description>Dezocine (0.1 mg/kg）will be infused during surgery</description>
    <arm_group_label>Dezocine</arm_group_label>
    <other_name>Dalgan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flurbiprofen Axetil</intervention_name>
    <description>Flurbiprofen Axetil (1 mg/kg）will be infused during surgery</description>
    <arm_group_label>Flurbiprofen axetil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult (&gt;/=18)

          2. Male or female

          3. Patients scheduled for abdominal surgery

          4. Undergoing catheterization

          5. Subject is American Society of Anesthesiologists (ASA) physical status 1 or 2

        Exclusion Criteria:

          1. Patient with bladder outflow obstruction

          2. Patient with overactive bladder (frequency greater than three times per night or more
             than eight times per 24 h)

          3. Patient with multisystemic diseases (central nervous system, cardiovascular system
             hepatic, psychiatric, and end-stage renal diseases)

          4. Patient with chemical substance abuse

          5. Patient with chronic pain

          6. Patient with morbid obesity

          7. Patient needs for urgent intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian-jun Yang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongda Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongda Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhongda Hospital</investigator_affiliation>
    <investigator_full_name>Jian-jun Yang</investigator_full_name>
    <investigator_title>Director, Department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Dezocine</keyword>
  <keyword>CRBD</keyword>
  <keyword>General anesthesia</keyword>
  <keyword>Urinary catheter</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flurbiprofen</mesh_term>
    <mesh_term>Flurbiprofen axetil</mesh_term>
    <mesh_term>Dezocine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

